Thus, as downstream transcription factors of TGF-β signaling, SMADs proteins could be the potential targets for therapeutic preventing and treatment of liver fibrosis as well as advanced liver diseases such as liver cirrhosis and HCC (3, 4). Here, TGFB1 is linked to Hepatic fibrosis.